Señales en vivo de IRWD | Maximiza tus Ganancias con Getagraph.com

COMPRAR 113609 min ago

@ $15.52

Emitido: 14 feb 2024 @ 13:33

Retorno: -47.68%

Señal anterior: feb 13 - 14:42

Señal anterior: Vender

Retorno: 2.37 %

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 12:02):

Stats
Volumen de hoy	589 954
Volumen promedio	4.54M
Capitalización de mercado	1.29B
EPS	$0 ( 2024-05-02 )
Próxima fecha de ganancias	( $0.190 ) 2024-06-18
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.260
ATR14	$0.00700 (0.09%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-15	Denner Alexander J	Buy	1 662	Class A Common Stock
2024-03-08	John Minardo	Buy	32 752	Class A Common Stock
2024-03-08	John Minardo	Sell	32 752	Performance-based Restricted Stock Unit
2024-03-08	Emany Sravan Kumar	Buy	37 120	Class A Common Stock
2024-03-08	Emany Sravan Kumar	Sell	37 120	Performance-based Restricted Stock Unit

INSIDER POWER
45.56
Last 100 transactions
Buy: 2 835 189 \| Sell: 1 035 601

Volumen Correlación

Largo: 0.21 (neutral)

Corto: 0.71 (moderate)

Signal:(30.187) Neutral

Ironwood Pharmaceuticals Correlación

10 Correlaciones Más Positivas
LUNG	0.956
NERV	0.942
GASS	0.905
BNIXU	0.902
IBRX	0.896
BNTX	0.888
RAPT	0.886
DBX	0.884
CREG	0.883
GOOD	0.883

10 Correlaciones Más Negativas
BZFD	-0.953
SYKE	-0.943
APOP	-0.924
KTOS	-0.921
PPD	-0.91
BLU	-0.91
SSIC	-0.909
BNIX	-0.905
TYHT	-0.904
ACVA	-0.903

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Ironwood Pharmaceuticals Correlación - Moneda/Commodity

0.52
( weak )

0.39
( neutral )

0.00
( neutral )

-0.45
( neutral )

0.42
( neutral )

Ironwood Pharmaceuticals Finanzas

Annual	2023
Ingresos:	$442.74M
Beneficio Bruto:	$441.16M (99.64 %)
EPS:	$-6.45

FY	2023
Ingresos:	$442.74M
Beneficio Bruto:	$441.16M (99.64 %)
EPS:	$-6.45

FY	2022
Ingresos:	$410.60M
Beneficio Bruto:	$409.18M (99.65 %)
EPS:	$1.130

FY	2021
Ingresos:	$413.75M
Beneficio Bruto:	$413.75M (100.00 %)
EPS:	$3.26

Financial Reports:

No articles found.

Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.